Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 17,540,089 shares of Dyne Therapeutics Inc. common stock, representing 10.7% of the class as of the event date. The firm has sole power to vote 17,517,597 of these shares and sole power to dispose of 17,540,089 shares, with no shared voting or dispositive power. T. Rowe Price classifies itself as an investment adviser and states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Dyne Therapeutics.
Dyne Therapeutics CEO and President, who is also a director, reported selling 2,662 shares of Common Stock on December 5, 2025 at a weighted average price of $20.72. The shares were automatically sold to satisfy tax withholding obligations tied to restricted stock units granted on December 4, 2024, under a restricted stock unit agreement that constitutes a binding contract consistent with the affirmative defense to liability under Rule 10b5-1, so the sale did not represent a discretionary trade.
After this transaction, the insider beneficially owns 196,877 shares directly, including 108,976 unvested RSUs, and 18,000 shares held in each of four trusts for the benefit of the reporting person’s children. The report notes that 2,662 shares were matchable under Section 16(b) with a prior purchase of 100,000 shares on July 14, 2025, and the reporting person has paid the issuer $31,111.88, representing the profit deemed realized on that short-swing transaction.
Dyne Therapeutics (DYN) furnished quarterly results. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and made it available as Exhibit 99.1.
The disclosure is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated. The common stock trades on the Nasdaq Global Select Market under the symbol DYN.
Dyne Therapeutics (DYN) filed its Q3 2025 10‑Q, reporting higher cash and continued R&D investment. Cash and cash equivalents were $573.6 million, with marketable securities of $218.3 million. Total assets reached $867.1 million. The company posted a Q3 net loss of $108.0 million ($0.76 per share) on operating expenses of $113.9 million, driven by research and development of $97.2 million and general and administrative of $16.7 million.
To strengthen liquidity, Dyne completed a public offering for net proceeds of $215.8 million and sold $140.6 million via its at‑the‑market program year‑to‑date. It also drew $100.0 million under a term loan with Hercules, due July 1, 2030, bearing interest at the prime rate (floor 7.50%) plus 2.45%. Long‑term debt, net, was $99.1 million. Shares outstanding were 142.6 million at quarter‑end.
Program updates include FDA Breakthrough Therapy Designation for z‑basivarsen (DM1) and initiation of a registrational expansion cohort in ACHIEVE. For z‑rostudirsen (DMD), the DELIVER 20 mg/kg Q4W registrational expansion cohort completed enrollment, with data planned in December 2025. Subsequent to quarter‑end, Dyne committed at least $25.5 million through March 2027 under a CMO manufacturing agreement.
Dyne Therapeutics, Inc. (DYN) director Brian S. Posner received a stock option grant on 10/01/2025 for 70,000 shares with an exercise price of $12.50. The option is exercisable for underlying common stock and shows 70,000 shares beneficially owned following the grant, reported as direct ownership. The option vests over three years in equal monthly installments through 10/01/2028, giving the director continuing equity alignment over that period. The Form 4 was signed on 10/02/2025 by an attorney-in-fact on behalf of the reporting person.
Brian S. Posner filed an SEC Form 3 as an initial statement of beneficial ownership for Dyne Therapeutics, Inc. (DYN). The event date is 10/01/2025 and the filing reports direct beneficial ownership of 8,500 shares of the issuer's common stock. The form identifies Mr. Posner as a Director and was signed on behalf of the reporting person by Ron Caponigro, Attorney-in-Fact on 10/02/2025. The filing includes a listed address in Waltham, MA and references a Power of Attorney (Exhibit 24.1).
Dyne Therapeutics appointed Brian Posner as a Class III director, with his term running until the 2026 annual stockholders’ meeting and subject to standard continuation conditions. The Board determined he qualifies as an independent director under Nasdaq rules and he is not serving on any Board committees.
Upon election, Posner received a stock option for 70,000 shares at an exercise price of $12.50 per share, vesting in equal monthly installments over three years, with full acceleration upon a change in control. He will also receive $45,000 in annual cash Board fees, additional annual equity grants under the non-employee director program, and reimbursement of reasonable travel and out-of-pocket Board-related expenses.
The company states there are no arrangements, family relationships, or related-party transactions involving Posner that require disclosure, and he will enter into Dyne’s standard indemnification agreement for directors.
Dyne Therapeutics insider sale tied to RSU vesting. John Cox, CEO & President and a director, reported on Form 4 an automatic sale of 2,640 shares of Dyne Therapeutics common stock on 09/05/2025 at a price of $13.41 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units granted December 4, 2024. After the sale, the filing shows the Reporting Person beneficially owned 199,539 shares directly and has 72,000 shares held indirectly in four trusts for children.
The filing discloses the sale was pursuant to a binding RSU agreement consistent with a Rule 10b5-1 affirmative defense and that 2,640 shares were matchable under Section 16(b) to a 100,000-share purchase on 07/14/2025. The Reporting Person paid the issuer $11,565.07 representing the profit deemed realized under Section 16(b). The report was signed by an attorney-in-fact on 09/09/2025.
Insider sales to satisfy RSU tax withholding reduced Johanna Friedl-Naderer's direct holdings in Dyne Therapeutics (DYN). On 09/04/2025 she reported automatic sales of 894 shares at a weighted average price of $13.27 (transactions ranged $13.08–$13.50) tied to RSUs that vested from a September 3, 2024 grant. On 09/05/2025 she reported automatic sales of 144 shares at $13.41 related to RSUs from a December 4, 2024 grant.
After these transactions her reported beneficial ownership declined from 95,017 to 94,873 shares. The filings state the sales were automatic to satisfy tax withholding and executed under a binding arrangement consistent with a Rule 10b5-1 plan; 74,514 RSUs remain unvested.
Dyne Therapeutics insider sale by Chief Medical Officer Kerr Douglas: On 09/04/2025 and 09/05/2025 Mr. Douglas reported automatic sales of common stock to satisfy tax withholding for vested restricted stock units. A total of 4,425 shares were sold (3,552 shares on 09/04 at a weighted-average price of $13.27 and 873 shares on 09/05 at $13.41). These sales were executed under binding RSU agreements consistent with Rule 10b5-1 affirmative defense and are described as automatic, not discretionary. After the reported transactions the reporting person beneficially owned 88,390 shares, which includes 74,625 unvested RSUs.